Nucleic Acid Based Therapeutics Report
: Analysis on the Market, Trends, and TechnologiesThe global nucleic acid–based therapeutics sector is entering a maturing phase marked by platform consolidation and targeted delivery innovation. The market is poised to expand to USD 12.46 billion by 2030 at a 14.29% CAGR, driven by growing investments and clinical successes in RNA and DNA modalities (Nucleic Acid Based Therapeutics Market Size, Share & Trends Analysis Report By Product, By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030). Over 3,431 companies are active in this field, underscoring widespread industry engagement across discovery, manufacturing, and clinical development. Key growth drivers include the rise of personalized medicine, expansion into extrahepatic tissues, and integration of artificial intelligence into target identification and delivery design.
We last updated this report 30 days ago. Tell us if you find something’s not quite right!
Topic Dominance Index of Nucleic Acid Based Therapeutics
To gauge the impact of Nucleic Acid Based Therapeutics, the Topic Dominance Index integrates time series data from three key sources: published articles, number of newly founded startups in the sector, and global search popularity.
Key Activities and Applications
- Engineering Advanced Delivery Vehicles
Development of lipid nanoparticles (LNPs), viral vectors (AAV), polymer carriers, and peptide-based systems to achieve tissue-specific targeting and repeated dosing with minimal off-target effects (Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery). - RNA Payload Optimization
Chemical modifications of mRNA, siRNA, and antisense oligonucleotides (ASOs) to enhance molecular stability, reduce immunogenicity, and extend in vivo duration. - Gene Editing and Modulation
Base editing, prime editing, and RNA editing approaches for precise correction of genetic mutations, pursued by companies advancing CRISPR/Cas and novel nuclease platforms. - Clinical Development and Trials
Execution of Phase I–III trials across indications from rare genetic disorders to oncology and infectious diseases, leveraging accelerated regulatory pathways and orphan-drug incentives. - Vaccine and Immunotherapy Applications
Use of mRNA and DNA platforms to encode antigens for prophylactic and therapeutic vaccines, including personalized cancer vaccines and next-generation infectious-disease prophylaxis.
Emergent Trends and Core Insights
- Platform Consolidation Around Delivery
As delivery remains the primary bottleneck, companies with scalable, adaptive delivery systems are gaining leverage; partners and acquirers focus on established LNP and AAV platforms. - AI-Accelerated Discovery
Artificial intelligence tools are being embedded into design pipelines to predict RNA-target interactions, optimize oligonucleotide sequences, and model delivery efficiency (Q&A: AI speeds up search for RNA-targeting drugs, opening new therapeutic possibilities). - Extrahepatic Targeting
Expansion beyond liver delivery into muscle, lung, brain, and kidney is a priority, with platform variants (e.g., Antibody-Oligonucleotide Conjugates) engineered for tissue specificity. - Diversification of RNA Modalities
Growth in circular RNA, self-amplifying RNA, and exon-editing RNA approaches, offering improved durability and functional versatility. - Combination and Personalized Therapies
Integration of nucleic acid therapeutics with cell therapies, small molecules, and immunotherapies to address complex disease mechanisms and enable individualized treatment regimens.
Technologies and Methodologies
- Lipid Nanoparticles (LNPs)
Leading non-viral carriers with tunable ionizable lipids and surface ligands, further refined for targeted biodistribution and reduced immunogenicity. - Adeno-Associated Virus (AAV) Vectors
Engineered capsids for cell-type specificity, immune evasion, and enhanced packaging capacity, applied in gene-replacement and gene-editing therapies. - Antisense Oligonucleotide Chemistries
Next-generation backbones (e.g., phosphorothioates, locked nucleic acids) for precise mRNA degradation and splicing modulation. - Gene Editing Platforms
CRISPR/Cas base editors and prime editors for single-base corrections without double-strand breaks, advancing curative strategies. - Peptide Conjugates and AOC Platforms
Antibody-Oligonucleotide Conjugates (AOCs) and receptor-targeted peptide carriers enabling cell-specific uptake and extrahepatic distribution.
Nucleic Acid Based Therapeutics Funding
A total of 1.3K Nucleic Acid Based Therapeutics companies have received funding.
Overall, Nucleic Acid Based Therapeutics companies have raised $312.0B.
Companies within the Nucleic Acid Based Therapeutics domain have secured capital from 5.7K funding rounds.
The chart shows the funding trendline of Nucleic Acid Based Therapeutics companies over the last 5 years
Nucleic Acid Based Therapeutics Companies
- Nuntius Therapeutics
Leverages proprietary delivery technology, machine learning, and nucleic acid engineering to develop mRNA therapies for oncology, respiratory, and neurodegenerative diseases. Its proprietary platforms focus on improving stability and precise tissue targeting, with early partnerships validating clinical potential. - Via Nova Therapeutics
Focuses on antiviral nucleic acid therapeutics for acute and subacute infections (influenza, rhinovirus, adenovirus), developing novel RNA-based agents to address gaps in effective antiviral treatments. The company’s strategic emphasis on unmet viral indications positions it for rapid clinical translation. - Judo Bio
Pioneers kidney-targeted siRNA delivery using its STRIKE platform (Selectively Targeting RNA Into KidnEy), enabling receptor-mediated uptake into proximal tubule cells. Initial programs aim to inhibit pathogenic solute carriers, addressing systemic and renal diseases with high unmet need. - TraffikGene
Academic spin-out developing peptide-based delivery solutions for diverse nucleic acids (mRNA, siRNA, pDNA) and proteins (Cas9). Its peptide vehicles demonstrate efficient, non-toxic, and extrahepatic targeting in preclinical in vitro and in vivo models. - DNA Nanobots
Applies DNA origami nanostructures for targeted therapeutic delivery, functionalized for chemotherapy, gene therapy, vaccines, and biosensing. Its modular approach pairs nucleic acid scaffolds with active payloads, aiming to improve precision and minimize off-target exposure.
Enhance your understanding of market leadership and innovation patterns in your business domain.
3.7K Nucleic Acid Based Therapeutics Companies
Discover Nucleic Acid Based Therapeutics Companies, their Funding, Manpower, Revenues, Stages, and much more
Nucleic Acid Based Therapeutics Investors
TrendFeedr’s Investors tool offers comprehensive insights into 5.1K Nucleic Acid Based Therapeutics investors by examining funding patterns and investment trends. This enables you to strategize effectively and identify opportunities in the Nucleic Acid Based Therapeutics sector.
5.1K Nucleic Acid Based Therapeutics Investors
Discover Nucleic Acid Based Therapeutics Investors, Funding Rounds, Invested Amounts, and Funding Growth
Nucleic Acid Based Therapeutics News
TrendFeedr’s News feature provides access to 25.7K Nucleic Acid Based Therapeutics articles. This extensive database covers both historical and recent developments, enabling innovators and leaders to stay informed.
25.7K Nucleic Acid Based Therapeutics News Articles
Discover Latest Nucleic Acid Based Therapeutics Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
Nucleic acid therapeutics have transitioned from discovery to execution, with delivery excellence emerging as the decisive competitive edge. Established firms refine LNP and AAV platforms, while specialized startups address extrahepatic targeting and novel RNA modalities. Artificial intelligence and bioinformatics are accelerating target discovery and payload design, enabling personalized, combination therapies. Strategic emphasis on platform scalability, regulatory navigation, and supply-chain resilience will define leadership. For stakeholders, aligning investments with delivery-centric platforms and AI-driven discovery engines promises the greatest returns as the field scales toward mainstream clinical adoption.
We value collaboration with industry professionals to offer even better insights. Interested in contributing? Get in touch!
